This article is more than 5 years old. Information may no longer be current.

Study: Jetrea releases vitreomacular traction in majority of eyes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PHILADELPHIA – Jetrea injection resulted in vitreomacular traction release in more than half of cases, a speaker here said, relating the Wills Eye experience with the treatment.

The presentation won the James S. Shipman Award for best paper during the Wills Eye Alumni Conference paper session.

“Intravitreal injection of ocriplasmin achieved [vitreomacular traction] release in approximately 61% of treated eyes with full-thickness macular holes. It also achieved a 36% closure rate for full-thickness macular hole . . . Smaller holes of less than 250 m were more likely to close,” Priya Sharma, MD, said. “Overall, our visual outcomes were favorable. No patients experienced a final loss of vision of more than two or three lines at last follow-up.”

The retrospective study included 103 eyes that were treated with Jetrea (ocriplasmin, ThromboGenics); 41 eyes had full-thickness macular hole (FTMH) at the time of injection.

The final analysis included 33 eyes that had more than 1-month follow-up. Eyes were evaluated on the day of injection and at 1 week, 1 month and final follow-up.

The primary endpoints were pharmacologic vitreomacular traction resolution, pharmacologic FTMH closure and FTMH size.

Mean patient age was 70 years.

Results showed that VMT release was achieved in 20 eyes (61%); mean time to release was 16 days (range, 3 to 76 days).

FTMH closure was achieved in 12 eyes (36%). Average time to closure was about 20 days, ranging from 4 to 32 days. FTMH hole reopened in one eye at about 2 years. Concurrent vitreomacular traction release occurred in 10 of 12 eyes that had FTMH closure.

The FTMH closure rate with subsequent vitrectomy was 100%.

Average baseline FTMH size less was than 250 m in 55% of eyes and 250 µm to 400 µm in 33% of eyes; 12% of eyes had a hole larger than 400 m.

Mean logMAR visual acuity improved significantly in all 33 eyes, from 0/90 (Snellen equivalent 20/159) at baseline to 0.40 (Snellen equivalent 20/40) at last follow-up (P < .0001).

Mean visual acuity improved significantly in the 12 eyes with pharmacologic FTMH closure, from 0.70 (Snellen equivalent 20/100) at baseline to 0.28 (Snellen equivalent 20/38) at last follow-up (P < .0002).

Mean visual acuity improved significantly in the 21 eyes without pharmacologic FTMH closure, from 1.02 (Snellen equivalent 20/209) at baseline to 0.47 (Snellen equivalent 20/59) at last follow-up (P < .0001). – by Matt Hasson

Disclosure: Sharma reports no relevant financial disclosures.